Otsuka (OTCMKTS:OTSKY) Reaches New 52-Week High – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s share price reached a new 52-week high on Thursday . The stock traded as high as $37.52 and last traded at $37.52, with a volume of 181 shares changing hands. The stock had previously closed at $34.92.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. UBS Group raised Otsuka to a “hold” rating in a research report on Tuesday, January 27th. Morgan Stanley upgraded shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. Finally, The Goldman Sachs Group cut shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Otsuka currently has an average rating of “Hold”.

Otsuka Price Performance

The company has a 50 day moving average of $34.24 and a 200 day moving average of $31.11. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The stock has a market capitalization of $38.86 billion and a price-to-earnings ratio of 15.27.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities research analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.86 EPS for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.